This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5 (cytochrome P450 3A5, an enzyme that metabolizes atazanavir). The hypothesis was that people with a slow-metabolizing genotype would have higher blood levels of atazanavir compared to people with the normal metabolizing genotype.

Any prescription, herbal, recreational, or over-the-counter medication contraindicated with ritonavir or atazanavir including, substrates/inhibitors/inducers of CYP3A/P-gp, cardio-active medication, or medications that alter the acid in the stomach. The study investigators will review each concurrent medication on a case-by-case basis.

Inability to refrain from grapefruit or grapefruit juice during the study.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01388543